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Abstract
In addition to its critical role in lysosomes for catabolism of sialoglycoconjugates, NEU1 is expressed at the plasma mem-
brane and regulates a myriad of receptors by desialylation, playing a key role in many pathophysiological processes. Here, 
we developed a proteomic approach dedicated to the purification and identification by LC–MS/MS of plasma membrane 
NEU1 interaction partners in human macrophages. Already known interaction partners were identified as well as several 
new candidates such as the class B scavenger receptor CD36. Interaction between NEU1 and CD36 was confirmed by com-
plementary approaches. We showed that elastin-derived peptides (EDP) desialylate CD36 and that this effect was blocked by 
the V14 peptide, which blocks the interaction between bioactive EDP and the elastin receptor complex (ERC). Importantly, 
EDP also increased the uptake of oxidized LDL by macrophages that is blocked by both the V14 peptide and the sialidase 
inhibitor 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA). These results demonstrate, for the first time, that binding 
of EDP to the ERC indirectly modulates CD36 sialylation level and regulates oxidized LDL uptake through this sialidase. 
These effects could contribute to the previously reported proatherogenic role of EDP and add a new dimension in the regula-
tion of biological processes through NEU1.
Keywords NEU1 · Elastin-derived peptides · Sialylation · CD36 · Atherosclerosis
Introduction
Sialidases, or neuraminidases, represent a family of exog-
lycosidases that remove terminal sialic acid residues from 
glycoproteins, glycolipids and oligosaccharides. The human 
sialidase family comprises four members: NEU1, NEU2, 
NEU3 and NEU4 [1]. Although initially described as a 
lysosomal sialidase, it is now clear from many reports that 
NEU1 is also expressed at the plasma membrane of cells and 
regulates a plethora of membrane receptors by desialylation 
[2] such as the toll-like receptor 4 (TLR4) [3], the TrkA 
tyrosine kinase receptor [4] and the insulin receptor [5]. As 
exemplified for TLR4, desialylation of the receptor by NEU1 
is essential for receptor activation, clustering, and cellular 
signaling in dendritic and macrophage cells [3]. It has fur-
ther been demonstrated that activation of ligand-induced 
TLR4 and subsequent signaling pathways may be brought 
by binding of complexes of NEU1 and matrix metallopro-
tease-9 (MMP-9) to TLR4 at the plasma membrane [6]. At 
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the plasma membrane, NEU1 also associated with the elas-
tin-binding protein (EBP) and the carboxypeptidase protec-
tive protein/cathepsin A (PPCA) forming the elastin receptor 
complex (ERC) which is required for elastogenesis and sig-
nal transduction through this receptor [7–9]. Consequently, 
NEU1 emerged not only as a catabolic enzyme but also as a 
key regulator of cell signaling and receptor activation. By its 
ability to interact with membrane receptors and to modulate 
their sialylation levels, NEU1 is a critical regulator of sev-
eral biological processes such as cell proliferation, differenti-
ation, elastogenesis and inflammation [2]. It has been further 
proposed that NEU1 may have important roles in vivo in 
tumorigenesis [10, 11] and in the biological effects mediated 
by the elastin-derived peptides (EDP) in age-related vas-
cular diseases [5, 12, 13]. Inhibition of NEU1 by the siali-
dase inhibitor 2-deoxy-2,3-didehydro-N-acetylneuraminic 
acid (DANA) decreases production of reactive oxygen spe-
cies (ROS) and reduces migration of mouse monocytes in 
response to EDP. Chimeric  LDLR−/− mice devoid of NEU1 
activity in their hematopoietic lineage also show reduced 
atherosclerosis [13]. Together, these data demonstrate that 
NEU1 may be a critical regulator of monocyte/macrophage 
functions. This has been further strengthened by the recent 
demonstration of a positive feedback loop between IL-1β, 
LPS and NEU1 in monocytes and macrophages that may 
promote atherosclerosis by enhancing a pro-inflammatory 
state [14].
In the present study, we investigated new roles for plasma 
membrane NEU1 sialidase in monocyte/macrophage func-
tions, by developing a proteomic approach to purify and 
identify by mass spectrometry the interaction partners of 
NEU1 in macrophages differentiated from THP-1 cells. We 
identified known interaction partners of NEU1 and sev-
eral new potential candidates such as the class B scaven-
ger receptor CD36. Interaction between NEU1 and CD36 
at the plasma membrane was confirmed by complementary 
approaches such as co-immunoprecipitation and Förster 
resonance energy transfer (FRET), and led to functional con-
sequences for CD36 sialylation and the uptake of oxidized 
LDL (oxLDL) by macrophages.
Materials and methods
Materials
The plasmid-encoding human PPCA was kindly provided 
by Pr Alessandra d’Azzo and is described elsewhere [15]. 
The plasmid-encoding NEU1-Flag and NEU1-HA con-
structs were obtained as detailed previously [16]. The plas-
mid-encoding human CD36 (pCI-CD36–12His) has been 
described previously [17]. The cDNA-encoding mono-
meric teal protein in a pcDNA3 vector was kindly provided 
by Pr Maddy Parsons [18]. Site-directed mutagenesis 
(Quikchange, Agilent) was used to engineer a NheI restric-
tion enzyme site upstream of the teal cDNA and a BstEII 
site in the coding sequence for a poly-glycine protein linker 
region that precedes the teal cDNA. The cDNA for CD36 
was excised from pCI-CD36-12His using NheI and BstEII 
and subcloned into the equivalent sites in pcDNA3-Teal to 
generate pCD36-Teal. The construct includes a consensus 
human ribosome binding site at the CD36 start codon and 
creates an in-frame fusion of CD36 with the poly-glycine 
linker and teal, such that the primary sequence of the prod-
uct now reads: CD36-SKTIKghlggggsggggssgVSKGEETT-
Teal. The NEU1-YFP construct was obtained using human 
NEU1 cDNA as template and the Phusion High-Fidelity 
DNA Polymerase (ThermoScientific). Restriction sites for 
HindIII and BamHI were introduced by PCR. After diges-
tion by the respective restriction enzymes, the resulting 
inset (NEU1) was ligated into a pcDNA3 vector encoding 
the YFP protein at the C terminus of the fusion protein. 
All cDNA sequences were confirmed by sequencing. EZ-
Link® sulfo-NHS-LC-biotin and monomeric avidin agarose 
beads were purchased from ThermoScientific. Free biotin, 
mouse monoclonal anti-Flag M2 antibodies and 2-O-(p-
nitrophenyl)-α-d-N-acetylneuraminic acid were from Sigma. 
Protein G Sepharose beads and streptavidin beads were 
purchased from GE healthcare. 2′-(4-Methylumbelliferyl)-
alpha-d-N-acetylneuraminic acid was from BioSynth and 
2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) 
and phorbol-12-myristate-13-acetate (PMA) from Calbio-
chem. Biotinylated Sambucus Nigra Agglutinin (SNA) was 
purchased from Vector laboratories and Dil-oxLDL from 
Alfa Aesar. The DIG glycan differentiation kit was from 
Roche. The V14 peptide (VVGSPSAQDEASPL) was syn-
thesized by Genecust with 99% purity. Rabbit polyclonal 
anti-NEU1 (H-300) antibodies were purchased from Santa 
Cruz and mouse monoclonal anti-CD36 antibodies from 
Santa Cruz and STEMCELL Technologies. Rabbit poly-
clonal anti-NEU3 were from Invitrogen. Rabbit monoclonal 
anti-HA and mouse monoclonal anti-β2-integrin antibodies 
were from Cell Signaling and Chemicon, respectively. Alexa 
Fluor 488 or 568-conjugated donkey anti-mouse or rabbit 
antibodies were from Invitrogen.
Kappa‑elastin preparation
EDP were prepared as described previously [7]. Briefly, 
insoluble elastin was prepared from bovine ligamentum 
nuchae by hot alkali treatment. Purity was assessed by com-
paring its amino acid composition to the one predicted from 
the elastin gene product. Soluble EDP were then obtained 
from insoluble elastin as described [7]. The obtained mixture 
of EDP, termed kappa-elastin (kE), has been shown to con-
tain several peptides harboring the bioactive motif GxxPG 
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[5]. The composition of EDP from kE was compared to EDP 
obtained after proteolysis of human elastin by neutrophil 
elastase by mass spectrometry analysis and shown to contain 
similar peptides harboring the bioactive GxxPG motif [5]. In 
addition, kE has been shown to exhibit the same biological 
properties as elastin hydrolysates obtained by human neu-
trophil elastase as both EDP mixtures increase pro-MMP1 
production in human skin fibroblasts with comparable extent 
[5, 19].
Cell culture and transient overexpression of NEU1
COS-7 cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% heat-inactivated fetal 
bovine serum, 100 units/mL penicillin, 0.1 mg/mL strep-
tomycin at 37 °C in a humidified atmosphere at 95% air 
and 5%  CO2. This cell line has been widely used to over-
express NEU1 [7, 16, 20–25]. Transient transfections were 
performed with JET-PEI (Polyplus Transfection), according 
to the manufacturer’s protocol, and experiments were per-
formed 48 h post-transfection. The human monocytic THP-1 
cell line was cultured in RPMI 1640 medium supplemented 
with 10% heat-inactivated fetal bovine serum, 100 units/mL 
penicillin and 0.1 mg/mL streptomycin. THP-1 monocytes 
were differentiated into adherent macrophages using 50 nM 
PMA (Calbiochem) for 72 h.
Purification of plasma membrane NEU1 and its 
interaction partners
Approximatively 4 × 107 COS-7 cells transfected with 
NEU1-Flag/PPCA (1:2) or 4.8 × 108 macrophages were 
washed three times in PBS, incubated with 0.5 mg/mL of 
EZ-Link® sulfo-NHS-LC-biotin for 30 min at 4 °C, and 
quenched with 100  mM glycine (30  min, 4  °C). Then, 
the cells were scraped in HEPES buffer (50 mM HEPES, 
150 mM NaCl, 2 mM EDTA, protease inhibitor cocktail, 
10 mM NaF, 2 mM  Na3VO4, pH 7.5) containing 1% Tri-
ton X-100, sonicated and incubated under gentle rotative 
mixing (3 h, 4 °C) for solubilization of membrane proteins. 
Lysates were then centrifuged (20,000g, 45 min, 4 °C) to 
pellet insoluble material and supernatants were incubated 
with monomeric avidin agarose beads for 45 min at 4 °C to 
purify biotinylated membrane proteins. After several washes, 
biotinylated proteins were eluted from beads by 10 mM free 
biotin in HEPES buffer under gentle rotative mixing at 4 °C 
and NEU1 complexes were immunoprecipitated using rab-
bit polyclonal anti-NEU1 antibodies pre-adsorbed onto 
protein G Sepharose beads (overnight, 4 °C). Non-specific 
interactions were controlled for using rabbit IgG-protein G 
Sepharose. Immunoprecipitated proteins were eluted with 
Laemmli buffer and the recovered proteins were denatured 
in SDS-PAGE loading buffer (62.5 mm Tris/HCl, pH 6.8, 
2% SDS, 10% glycerol, 0.5% bromophenol blue) for 10 min 
at 95 °C. Samples were subjected to SDS-PAGE on a 10% 
polyacrylamide gel, and proteins were stained by Coomassie 
blue. For detection of NEU1-Flag, proteins were transferred 
onto a nitrocellulose membrane. After blocking, membranes 
were incubated with mouse monoclonal anti-Flag M2 
(1/1000, overnight, 4 °C) and immunoreactive bands were 
revealed using a HRP-conjugated anti-mouse IgG (1/10,000) 
followed by enhanced chemiluminescence detection reagents 
(GE Healthcare) and visualized with the Odyssey Fc scanner 
(LI-COR).
Protein identification by LC–MS/MS
Each gel lane was systematically excised into 23 bands. Gel 
bands were diced into small pieces, destained using ammo-
nium bicarbonate and further reduced and alkylated with 
dithiothreitol and iodoacetamide, respectively. The in-gel 
digestion was carried out by adding an excess of trypsin 
solution to each sample and incubation for 14 h at 37 °C. 
The released peptides were extracted with 50% acetoni-
trile/0.1% formic acid. The acetonitrile was removed in a 
Speed Vac and the samples were reconstituted in 0.1% TFA. 
The peptide mixtures were analyzed on an Ultimate 3000 
RSLCnano system coupled to an Orbitrap Fusion Tribrid 
mass spectrometer (Thermo Fisher Scientific). Briefly, the 
samples were loaded on the trap column (Acclaim Pep-
Map RP-C18, 300 µm × 5 mm, 5 µm, 100 Å) and washed 
with water containing 0.1% TFA for 15 min (30 µl min−1), 
before the peptides were separated on the separation col-
umn (Acclaim PepMap RP-C18, 75 μm × 250 mm, 2 µm, 
100 Å) using gradients from 1 to 35% B (90 min), 35 to 
85% B (5 min) followed by 85% B (5 min), with solvent A: 
0.1% FA in water and solvent B: 0.08% FA in acetonitrile. 
MS and MS/MS experiments were performed on the Orbit-
rap Fusion, which was equipped with a Nanospray Flex Ion 
Source. Data were acquired in the data-dependent MS/MS 
mode: Each high-resolution full-scan (automatic gain con-
trol (AGC) target value 4 × 105, maximum injection time 
50 ms) in the Orbitrap (m/z 300–1500, R = 120,000) was fol-
lowed by high-resolution product ion scans in the Orbitrap 
(collision-induced dissociation, CID), 35% normalized colli-
sion energy, R = 15,000, AGC target value 5 × 104, maximum 
injection time 200 ms) within 5 s, starting with the most 
intense signal in the full-scan mass spectrum (quadrupole 
isolation window 2 Th). Dynamic exclusion for 60 s (mass 
window ± 2 ppm) was enabled to allow analysis of less abun-
dant species. Data acquisition was controlled with Xcali-
bur 3.0.63. Peptides were identified by automated de novo 
sequencing followed by matching to the UniProt/Swiss-Prot 
database using the software PEAKS Studio (version 7.5; 
Bioinformatics Solutions, Waterloo, Canada). The enzyme 
was set to ‘trypsin’ and a maximum of one missed cleavage 
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was allowed. Carbamidomethylation was considered as fixed 
modification and oxidation of methionine and deamidation 
of glutamine and asparagine residues were chosen as vari-
able modifications. Mass error tolerances for precursor and 
fragment ions were set to 3 ppm and 0.015 Da, respectively. 
The peptide score threshold was decreased until a false dis-
covery rate of ≤ 2% on the peptide spectrum match level 
was reached and a minimum of two unique peptides were 
required for protein identification. Two independent puri-
fications were performed, and protein identifications were 
compared to a control purification using rabbit IgG. Proteins 
identified in both conditions were considered as non-specific 
and discarded.
Sialidase activity
For the determination of sialidase activity bound to avidin 
beads, beads were washed with PBS and directly resus-
pended in a reaction buffer containing 20 mM MES (pH 4.5) 
and 200 µM 2-O-(p-nitrophenyl)-α-d-N-acetylneuraminic 
acid for 4 h at 37 °C in the dark. Reactions were stopped by 
adding 1 M  Na2CO3 and the absorbance measured using an 
Infinite F200 PRO microplate reader (TECAN).
Sialidase activity at the plasma membrane of mac-
rophages transfected, or not, with negative control siRNA 
or NEU1 siRNA, was performed as described previously 
for human fibroblasts [7]. Cells, seeded in 12-well culture 
dishes (5 × 105 cells/well), were washed with PBS and incu-
bated with a reaction buffer containing 20 mm  CH3COONa 
(pH 6.5) and 400 µM 2′-(4-methylumbelliferyl)-α-d-N-
acetylneuraminic acid, with or without kE (50 µg/mL), for 
2 h at 37 °C in the dark. After incubation, the reaction was 
stopped by adding 0.4 M glycine buffer (pH 10.4), and the 
fluorescent 4-methylumbelliferone product released in the 
medium was measured using the Infinite F200 PRO micro-
plate reader (TECAN).
NEU1 siRNA gene silencing
Silencer™ predesigned siRNA (ID:8481, Ambion) targeting 
exon 2 of the human NEU1 gene were used to silent NEU1 
[7, 26]. THP-1 cells (1.5 million) were transfected in 6-well 
culture dishes with either 50 nM NEU1 siRNA or nega-
tive control siRNA (Ambion) using INTERFERin reagent 
(Polyplus Transfection) according to the protocol provided 
by the manufacturer. Twenty-four hours after transfection, 
THP-1 cells were counted, transferred in 12-well culture 
dishes (500,000/well) and differentiated into adherent mac-
rophages using 50 nM PMA for 72 h before measurement 
of sialidase activity. GAPDH siRNA (Ambion) was used 
as a positive control for optimization of transfection condi-
tions and siRNA efficacy was verified at the protein level by 
Western blotting.
Immunofluorescence
Macrophages or COS-7 cells transfected with NEU1/PPCA 
(1:2) and CD36 were grown on sterile coverslips in 24-well 
plates and stimulated, or not, with kE (50 µg/mL, 1 h). After 
three washes in PBS, cells were fixed with 2% paraformal-
dehyde in PBS for 15 min and permeabilized by 0.2% Triton 
X-100 in PBS for 10 min. After blocking with 10% goat 
serum in PBS for 1 h, cells were incubated with rabbit poly-
clonal anti-NEU1 (2 µg/mL) and mouse monoclonal anti-
CD36 (2 µg/mL) in PBS containing 1% BSA overnight at 
4 °C. Coverslips were then washed three times with PBS and 
incubated with Alexa Fluor 488-conjugated goat anti-mouse 
and Alexa Fluor 568-conjugated goat anti-rabbit antibodies 
(1/1000) in PBS containing 1% BSA for 1 h at room tem-
perature. Coverslips were mounted, visualized with a laser 
scanning microscope (LSM 710 NLO, Zeiss) and analyzed 
by Image J software.
Spectral FRET measurement
COS-7 cells transfected with NEU1-YFP/PPCA (1:2) and/
or CD36-Teal were grown on sterile coverslips in 24-well 
plates and stimulated, or not, with kE (50 µg/mL, 1 h). After 
three washes in PBS, cells were fixed with 2% paraform-
aldehyde in PBS for 15 min and washed with PBS. After 
coverslips mounting, FRET images were acquired using the 
Laser Scanning Microscope LSM 710 NLO (Zeiss). Samples 
were excited with 458 nm wavelength (2% power) and emis-
sion signal was collected between 420 and 721 nm through 
63× oil objective (ON: 1.4) on 32 spectral channels. Image 
parameters were 512 × 512 pixels, 16 bits and acquisition 
were done with sum on 16 scans to optimize the signal to 
noise ratio. Separate images were, respectively, acquired 
from energy donor alone (CD36-Teal) and energy acceptor 
alone (NEU1-YFP) samples at 458 nm and 514 nm, respec-
tively, to have the corresponding emission spectra.
FRET analysis
FRET analysis was based on the protocol described by 
Leavesley et al. [27]. The first part of spectral images pro-
cessing was done using ZEN software (Zeiss). Images were 
filtered with median 3 × 3 and the linear unmixing algorithm 
with measured references spectra of Teal and YFP were pro-
cessed. Each pixel of the spectral image can then be 
described by the following equation: Isp = CD × ISpD + CA × 
ISPA + R; where ISPD and ISPA are the donor and acceptor 
spectra, respectively, CD and CA are the donor and acceptor 
spectra contribution, respectively, and R is the residue signal 
which was unidentified by the algorithm. The second part of 
analysis was done using homemade ImageJ macro to deter-
mine FRET efficiency using the following equation: 
795Identification of CD36 as a new interaction partner of membrane NEU1: potential implication…
1 3
E
FRET
=
C
A
C
A
+C
D
× 100 . For each cell, thirty regions of inter-
est (ROI of 0.62 µm2) contouring the cell were chosen, and 
the mean E
FRET
 was measured.
Co‑immunoprecipitation
COS-7 cells transfected with NEU1-HA/PPCA (1:2) and 
CD36 were washed three times in PBS, resuspended in 1 mL 
cold TEM buffer (75 mM Tris, 2 mM EDTA, 12 mM  MgCl2, 
protease inhibitor cocktail, 10 mM NaF, 2 mM  Na3VO4, pH 
7.5) containing 1% CHAPS. After sonication, lysates were 
centrifuged at 600g for 10 min to remove nuclei and non-
lysed cells. Samples were solubilized during 3 h at 4 °C 
under gentle end-over-end mixing. After centrifugation at 
20,000g during 45 min at 4 °C, the supernatant was recov-
ered. Immunoprecipitations were performed using 2 µg of 
rabbit monoclonal anti-HA or 1 µg mouse monoclonal anti-
CD36 pre-adsorbed on protein G Sepharose beads for 2 h 
at 4 °C.
For macrophages, crude membranes were prepared. Cells 
were washed three times in PBS and resuspended in 1 mL 
cold TEM buffer without detergent. After sonication, lysates 
were centrifuged at 600g for 10 min to remove nuclei and 
non-lysed cells and crude membranes were pelleted by cen-
trifugation at 20,000g during 45 min at 4 °C. The super-
natant, corresponding to the cytosol fraction, was recov-
ered. Membrane proteins were then solubilized from crude 
membrane pellets in TEM buffer containing 1% CHAPS 
(3 h, 4 °C) and centrifuged at 20,000g (45 min, 4 °C). The 
supernatant, corresponding to solubilized crude membrane 
proteins, was recovered. Efficient cell fractionation was con-
firmed by evaluating the partitioning of β2-integrin between 
cytosol and crude membrane fractions by Western blot. 
Immunoprecipitations were then performed on crude mem-
brane fractions using 2 µg of rabbit polyclonal anti-NEU1 or 
1 µg mouse monoclonal anti-CD36 pre-adsorbed on protein 
G Sepharose beads for 2 h at 4 °C. After several washes, 
immunoprecipitated proteins were eluted with SDS-PAGE 
loading buffer and subjected to SDS-PAGE and immunob-
lotting. Immunoblottings were performed using the indicated 
antibodies and immunoreactivity was revealed using HRP-
conjugated secondary antibodies (1/10,000) as described 
above.
Lectin blotting and lectin pulldown
Lectin blotting was performed using the DIG glycan dif-
ferentiation kit (Roche) according to the manufacturer’s 
instructions and as described previously [5]. Briefly, after 
immunoprecipitation of CD36 from transfected COS-7 
cells, nitrocellulose membranes were probed with either 
digoxigenin-labeled Sambucus nigra agglutinin (SNA) 
which binds specifically to sialic acids terminally linked to 
galactose or N-acetylgalactosamine (α-2,6), or digoxigenin-
labeled Maackia amurensis agglutinin (MAA) which binds 
to galactose (α-2,3). Detection of lectin binding to the mem-
branes was revealed by anti-digoxigenin antibodies coupled 
to alkaline phosphatase. As described above, detection of 
immunoprecipitated CD36 was revealed by a mouse mono-
clonal anti-CD36 (1/500) followed by HRP-conjugated anti-
mouse (1/10,000).
Lectin pulldown was performed on transfected COS-7 
cells or macrophages stimulated, or not, with kE (50 µg/mL), 
kE/V14 (1:2 molar ratio) or V14 alone for 1 h at 37 °C. Cells 
were washed three times in PBS and resuspended in 1 mL 
cold Tris/NaCl buffer (100 mM Tris, 80 mM NaCl, protease 
inhibitor cocktail, 10 mM NaF, 2 mM  Na3VO4, pH 8) with-
out detergent. After sonication, lysates were centrifuged at 
600g for 10 min to remove nuclei and non-lysed cells and 
crude membranes were pelleted by centrifugation at 20,000g 
during 45 min at 4 °C. After solubilization in Tris/NaCl 
buffer containing 1% NP-40 for 3 h at 4 °C, samples were 
centrifuged at 20,000g (45 min, 4 °C) and the supernatant 
(solubilized crude membrane proteins) was recovered. For 
each condition, equal amounts of membrane proteins were 
incubated with 50 μg/mL biotinylated SNA (overnight, 
4 °C). Streptavidin agarose beads were then added for 1 h 
at 4 °C. The beads were washed once with TBS/1% Triton 
X-100 and twice with TBS/0.5% Triton X-100, and directly 
resuspended in SDS-PAGE loading buffer, boiled and sub-
jected to SDS-PAGE and immunoblotting. Immunoblottings 
were performed using mouse monoclonal anti-CD36 (1/500) 
and immunoreactivity was revealed using HRP-conjugated 
anti-mouse (1/10,000) as described above.
Uptake of oxLDL
Uptake of DiI-oxLDL was studied as described previously 
[28]. Adherent macrophages in 24-well plates (250,000/
well) were incubated, or not, with kE (50 µg/mL), DANA 
(400 µM), DANA/kE, kE/V14 (1:2 molar ratio) or V14 alone 
for 1 h at 37 °C. Then, cells were incubated with 10 µg/mL 
DiI-oxLDL for 4 h at 37 °C. Thereafter, cells were washed 
three times with PBS containing 2 mg/mL BSA, twice with 
PBS and fixed with 2% paraformaldehyde in PBS for 15 min. 
After washes, coverslips were mounted and visualized with 
an invert fluorescent microscope (AXIO, Zeiss). The main 
gray value per field was calculated using the “Integrated 
Density” parameter of Image J software from ten different 
fields per condition.
Statistical analysis
Results are expressed as mean ± SEM. Statistical signifi-
cance was evaluated using paired or unpaired Student’s t 
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test, or one-way ANOVA followed by a Dunnett’s multiple 
comparisons test, and p values of less than 0.05 were con-
sidered as statistically significant.
Results and discussion
Although NEU1 sialidase has been referred to as a lysoso-
mal member of the sialidase family [29], accumulative data 
from the last 10 years have shown that NEU1 is also present 
at the plasma membrane of cells and regulates a myriad of 
membrane glycoproteins by desialylation such as the inte-
grin beta 4 [30], TLR4 [3], Trk A [4], PDGF-BB and IGF 
receptors [31], EGF and MUC1 receptors [32], and CD31 
[20]. This novel role for NEU1 as regulator of membrane 
receptor sialylation offers new dimensions in the regulation 
of cell signaling and modulation of biological functions 
[2]. Moreover, NEU1 was proposed at the center of larger 
signaling platforms involving G-protein-coupled receptors, 
a matrix metalloproteinase (MMP-9) and other receptors 
such as receptor tyrosine kinases or TLR4 [6, 33, 34]. At 
the plasma membrane, NEU1 is also part of the ERC and 
is involved in elastogenesis and signal transduction through 
this receptor [7–9], and in the biological effects mediated by 
EDP in atherosclerosis [13], thrombosis [35], and develop-
ment of insulin resistance [5]. Consequently, NEU1 now 
emerges not only as a catabolic enzyme but also as a key 
actor involved in cell signaling regulation, membrane recep-
tor activation and vascular diseases. Deciphering the pro-
tein complexes that associated with NEU1 at the plasma 
membrane of cells will help in better understanding new 
roles played by this sialidase in biological processes. In the 
current study, a proteomic approach was developed to purify 
and identify new interaction partners of NEU1 sialidase at 
the plasma membrane of macrophages, critical players of 
atherosclerosis.
Settings of the proteomic approach in COS‑7 cells 
overexpressing NEU1
As NEU1 is expressed both at the plasma membrane and 
intracellularly, mainly in lysosomes, a two-step purification 
procedure was used to specifically purify plasma membrane 
NEU1 and its interacting partners. As illustrated in Fig. 1a, 
the first step involved biotinylation of plasma membrane 
proteins from COS-7 cells overexpressing NEU1-Flag with 
the non-permeable reagent EZ-Link® sulfo-NHS-LC-biotin. 
After cell lysis, protein lysates were incubated with mono-
meric avidin agarose beads to retain biotinylated plasma 
membrane proteins. After elution by free biotin, recovered 
proteins were subjected to immunoprecipitation using poly-
clonal rabbit anti-NEU1 antibodies. Bound material was 
then eluted from beads, fractionated by SDS-PAGE and 
stained by Coomassie blue. After systematic excision from 
the gel and trypsin digestion, the extracted peptides were 
analyzed by LC–MS/MS. Settings of the approach were 
first performed from small-scale purifications using COS-7 
cells overexpressing NEU1-Flag and PPCA, as previously 
reported [16], and the presence of NEU1-Flag was checked 
at each step of the procedure by Western blot analysis 
(Fig. 1b). NEU1-Flag was detected in the starting material 
(input), bound onto avidin beads (avidin beads), in the free 
biotin eluates (biotin eluates) and finally recovered at the 
end of the procedure after elution from protein G Sepharose 
beads with Laemmli buffer (protein G Sepharose beads). 
As shown previously, transient expression of NEU1 gives 
rise to multiple protein species of molecular weight between 
40- and 55-kDa due to differential glycosylations of NEU1 
[16, 36].
Sialidase activity bound to monomeric avidin beads 
was next measured using the 2-O-(p-nitrophenyl)-α-d-N-
acetylneuraminic acid as substrate. To avoid any potential 
interference with the Flag tag, COS-7 cells overexpressing 
non-tagged NEU1 were subjected to the first step of the 
purification procedure and monomeric avidin beads were 
directly resuspended in 20 mM MES buffer (pH 4.5) con-
taining 200 µM of substrate. As shown in Fig. 1c, sialidase 
activity of the avidin bead fractions was 6.4-fold higher for 
COS-7 cells overexpressing NEU1 compared to non-trans-
fected cells. Taken together, these results demonstrated that 
plasma membrane NEU1 was readily recovered at the end 
of the two-step purification and remained functional before 
immunoprecipitation with anti-NEU1 antibodies.
Validation of the proteomic approach in human 
macrophages endogenously expressing NEU1
The whole protocol was then applied to human macrophages 
whose ability to produce inflammatory cytokines and pro-
teases, to form foam cells and their involvement in effero-
cytosis and autophagy make macrophages critical actors in 
the development of local inflammatory responses and ath-
erosclerotic lesion growth [37]. Differentiation of mono-
cytes into macrophages is associated with increase in NEU1 
expression and its translocation from the lysosomes to the 
cell surface, concomitant with a 12- to 14-fold increase in 
sialidase activity [26, 38]. Interestingly, cell surface α2-3- 
and α2-6-linked sialic acids decreased after monocyte dif-
ferentiation into macrophages, which is in accordance with 
the elevated activity of endogenous NEU1 sialidase [39]. 
Moreover, we and others have demonstrated that NEU1 siali-
dase plays a key role in monocyte/macrophage functions 
such as phagocytosis, cytokine release [26, 40], monocyte 
migration and ROS production in response to EDP [13]. 
Herein, macrophages were obtained by differentiation from 
the human monocytic THP-1 cell line, a well-known model 
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to study monocyte/macrophage functions, mechanisms and 
signaling pathways, and which produce similar response 
patterns compared to human peripheral blood mononuclear 
cells [41, 42]. Differentiation of monocytes by phorbol-
12-myristate-13-acetate (PMA) has been shown to produce 
M0 macrophages which had 20% and 30% reduction in α2-3- 
and α2-6-linked sialic acids at their cell surface, respectively 
[39]. Interestingly, polarization to M1 or M2 subtypes had 
no further effect on the membrane sialylation level [39], sug-
gesting that the main modifications occurring at the levels 
of NEU1 and membrane sialidase activity occur during the 
differentiation into M0 macrophages.
The ultimate goal of such a two-step purification proce-
dure is the purification of sufficient amounts of the target 
A
B C
NEU1-Flag
cDNA
- + - + - + - +
NEU1 - +
NEU1-Flag
Fig. 1  Workflow of the proteomic approach and validation of the 
purification procedure. a The approach uses a two-step purification. 
The first step involves biotinylation of plasma membrane proteins 
from adherent COS-7 cells overexpressing NEU1-Flag with the non-
permeable reagent EZ-Link® sulfo-NHS-LC-biotin. After cell lysis, 
protein lysates were incubated with monomeric avidin agarose beads 
to retain biotinylated plasma membrane proteins. After elution by free 
biotin, recovered proteins were subjected to the second step of puri-
fication which consists of immunoprecipitation of NEU1 and asso-
ciated interaction partners using polyclonal rabbit anti-NEU1 anti-
bodies. Bound material was then eluted from beads, fractionated by 
SDS-PAGE and stained by Coomassie blue. After systematic excision 
from the gel and in-gel trypsin digestion, the extracted peptides were 
analyzed by nano-LC–ESI MS/MS using an Orbitrap mass spectrom-
eter. b COS-7 cells overexpressing human NEU1-Flag were subjected 
to the purification procedure (a) and the presence of NEU1-Flag at 
each step of the purification was checked by Western blot using a 
mouse monoclonal anti-Flag antibody (1/1000). The figure is repre-
sentative of three independent experiments. NEU1-Flag−, non-trans-
fected cells; NEU1-Flag+, cells co-transfected with NEU1-Flag and 
PPCA. c Sialidase activity associated with monomeric avidin agarose 
beads was measured using 200  µM of 2-O-(p-nitrophenyl)-α-d-N-
acetylneuraminic acid substrate in 20 mM MES at pH 4.5. Results are 
expressed as mean ± SEM of four independent experiments and statis-
tical analysis was performed by Student’s t test (*p < 0.05). NEU1− 
non-transfected cells; NEU1+ cells co-transfected with NEU1 and 
PPCA
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protein to identify associated proteins by mass spectrometry 
analysis. To reach this goal, about 480 million macrophages 
were used and submitted to the whole procedure. Proteins 
recovered at the end of the purification were separated by 
one-dimensional gel electrophoresis and stained by Coomas-
sie Blue (Fig. 2a, left panel, lane 2). As a control, protein 
G Sepharose beads coated with anti-NEU1 antibodies were 
also subjected to one-dimensional gel electrophoresis and 
Coomassie Blue staining to visualize bands corresponding 
to anti-NEU1 antibodies and to identify the non-specific 
proteins provided by the coated beads alone (Fig. 2a, left 
panel, lane 3). Two major bands migrating around 50- and 
60-kDa, respectively, were recovered in both lanes (Fig. 2a, 
left panel, asterisks). In contrast to the coated beads alone 
(lane 3), several additional bands were also detected over the 
whole lane 2 after the purification procedure. As illustrated 
for lane 2 (Fig. 2a, right panel), lanes were systematically 
excised into 23 bands, in-gel digested with trypsin, and the 
resulting peptides were analyzed by mass spectrometry and 
identified from UniProt/Swiss-Prot databases. As expected, 
MS/MS identifies the two major bands migrating around 50- 
and 60-kDa (Fig. 2a, left panel, asterisks) as IgG and serum 
albumin. Importantly, MS/MS identification confirmed 
the presence of NEU1 in lane 2 (Fig. 2b) between 34- and 
55-kDa and around 95-kDa in agreement with its glycosyla-
tion profile and its ability to form dimeric structures [16, 36]. 
In addition, already known interacting partners of NEU1 
and/or proteins already known to be regulated by NEU1 
were unambiguously identified such as integrin beta-2, 
lysosome-associated membrane glycoprotein 2 (LAMP2), 
matrix metalloproteinase-9 (MMP-9), platelet endothelial 
cell adhesion molecule (PECAM) and toll-like receptor 2 
72
55
43
34
26
95
130
kDa
170
A
B
integrin β2, TLR2
integrin β2
integrin β2, LAMP2, MMP-9, PECAM
integrin β2, NEU1
MMP-9
*
*
*
*
2
NEU1
NEU1
NEU1
NEU1
NEU1
Fig. 2  Large-scale purification of membrane NEU1 and identifica-
tion of already know interaction partners. a Left panel: 4.8 × 108 
macrophages differentiated from THP-1 cells were submitted to the 
purification protocol and proteins recovered at the end of the purifica-
tion were separated by SDS-PAGE and stained by Coomassie Blue 
(lane 2). Lane 1, protein lysate (starting material); lane 3, proteins 
recovered after elution with Laemmli buffer of protein G Sepharose 
beads coated with anti-NEU1 antibodies only. Asterisks, non-specific 
protein bands recovered in both lanes 2 and 3. Right panel: as illus-
trated for lane 2, lanes were excised into 23 bands and in-gel digested 
by trypsin for analysis by mass spectrometry. b Identification by LC–
MS/MS of already know interaction partners of membrane NEU1. 
Trypsin-digested protein bands were analyzed by nano-LC–ESI 
MS/M, and proteins identified with Mascot software in Swiss-Prot 
and trEMBL databases
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(TLR2) (Fig. 2b). Taken together, these data validate the 
procedure used.
Identification of potential interaction partners 
of membrane NEU1 in human macrophages
In addition to the identification of already known interact-
ing partners of NEU1 (Fig. 2b), 71 unique proteins were 
unambiguously identified by mass spectrometry from two 
independent experiments (Table 1). These candidates that 
remain to be confirmed in further experiments, showed 
localization to different subcellular compartments (plasma 
membrane, cytosol and cytoskeleton) and could be divided 
into five distinct groups: membrane-bound, transmembrane, 
signaling, and cytoskeleton proteins, and proteins involved 
in vesicle trafficking. This indicates that NEU1 may associ-
ate with different protein complexes at the plasma membrane 
of macrophages, as originally proposed by the group of Sze-
wczuk and co-workers by the discovery of membrane signal-
ing platforms involving NEU1, MMP-9, a G-protein-coupled 
receptor (GPCR) and either the insulin receptor or TLR4 [6, 
33, 34, 43]. Formation of such complexes has been reported 
to play important role in reciprocal receptor transactivation 
[6, 33, 34, 43]. As exemplified for GPCR-associated protein 
complexes [44], protein complexes are dynamic assemblies 
and their composition may change according to the presence 
of agonists. It is tempting to speculate that such modulation 
may occur within NEU1-associated complexes under differ-
ent pathophysiological contexts such as during inflammatory 
conditions.
Among the proteins identified in the two independ-
ent experiments, the class B scavenger receptor CD36, 
also known as platelet glycoprotein 4, was identified with 
5 unique peptides covering 14% of the whole amino acid 
sequence of CD36 (Table 1). This plasma membrane gly-
coprotein heavily modified post-translationally by N-linked 
glycosylation with 9 out the 10 putative glycosylation sites 
being modified [17]. CD36 is expressed in monocytes, mac-
rophages, and also in platelets, epithelial, endothelial and 
smooth muscle cells, binds many different ligands and is 
involved in several diseases scenarios such as inflamma-
tion, atherosclerosis, thrombosis and angiogenesis [45, 46]. 
In atherosclerosis, CD36 plays significant roles including 
foam cell formation, release of inflammatory mediators, 
macrophage trapping and thrombosis [46].
Validation of the interaction between NEU1 
and CD36 and functional consequences 
on the sialylation level of CD36
Validation of the interaction between NEU1 and CD36 was 
first performed in COS-7 cells overexpressing non-tagged 
NEU1 and CD36. As shown in Fig. 3A, transfected NEU1 
localized at the plasma membrane and inside the cells, 
mainly in lysosomes, as previously described [16]. Trans-
fected CD36 was also detected both intracellularly and at the 
plasma membrane and showed colocalization with NEU1. 
Confocal FRET imaging analysis in COS-7 cells transfected 
with CD36-Teal (energy donor) and NEU1-YFP (energy 
acceptor) provided additional evidence that both proteins 
were in sufficient proximity to interact with each other at the 
plasma membrane (Fig. 3B). In cells transfected with CD36-
Teal alone, excitation of the donor at 458 nm led to a resid-
ual fluorescence emission at 527 nm, corresponding to the 
wavelength of acceptor emission. This cross-talk was cor-
rected using FRET analysis based on spectral unmixing (see 
“Materials and methods”), and non-specific FRET efficiency 
was estimated at 0.3 ± 0.2%. When cells were co-transfected 
with both CD36-Teal and NEU1-YFP, FRET efficiency in 
the colocalization areas at the plasma membrane was sig-
nificantly increased to 9.0 ± 0.7%. At the plasma membrane, 
NEU1 is part of the ERC and is required for elastogenesis 
and signal transduction through this receptor [7–9]. NEU1 
constitutes the catalytic subunit of the receptor [7, 9] and 
stimulation of cells by EDP that originate from elastin deg-
radation during vascular aging [12], triggers NEU1 sialidase 
activity and signal transduction. We therefore evaluated the 
effects of EDP, derived from organo-alkaline hydrolysate 
of insoluble bovine purified elastin (kappa-elastin, kE), 
on FRET efficiency between CD36-Teal and NEU1-YFP. 
When cells were stimulated by kE (50 µg/mL), FRET effi-
ciency in the colocalization areas at the plasma membrane 
was 10.5 ± 0.8% (Fig. 3B). Although not significant, this 
slight increase in FRET efficiency observed between non-
stimulated (w/o) and stimulated (kE) cells, may suggest con-
formational changes within the CD36-NEU1 complex that 
lead to reorientation of the FRET pair and optimization of 
energy transfer. Interaction between NEU1 and CD36 was 
further confirmed by co-immunoprecipitation from whole 
cell lysates. Immunoprecipitation of NEU1-HA in COS-7 
cells co-expressing NEU1-HA and CD36 led to a significant 
increase by 44.3 ± 15.8% of the amount of co-immunopre-
cipitated CD36 compared to cells expressing CD36 alone 
(Fig. 3C). Reciprocally, immunoprecipitation of CD36 in 
cells co-expressing CD36 and NEU1-HA led to a significant 
increase by 93.0 ± 24.4% of the amount of co-immunopre-
cipitated NEU1-HA compared to cells expressing NEU1-HA 
alone (Fig. 3D).
Although much is known about the glycosylation sta-
tus of CD36 [17], less is known about its sialylation. We 
therefore assessed the presence of sialic acids terminally 
linked to galactose or N-acetylgalactosamine (α2-6) or to 
galactose (α2-3) on immunoprecipitated CD36 from trans-
fected COS-7 cells using the digoxigenin-coupled Sambu-
cus nigra (Dig-SNA) or Maackia amurensis (Dig-MAA) 
lectins, respectively. As shown in Fig. 3E, and in contrast 
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Table 1  Protein identification by LC–MS/MS
UnitProt accession number Protein name % coverage Number 
of unique 
peptide
Average 
molecular 
mass (kDa)
Band no.
Membrane-bound proteins
 Q96CX2|KCD12_HUMAN BTB/POZ domain-containing protein KCTD12 16 4 35.7 7
 Q9UGN4|CLM8_HUMAN CMRF35-like molecule 8 9 2 33.2 16, 17
 O75131|CPNE3_HUMAN Copine-3 6 2 60.1 13
 Q99961|SH3G1_HUMAN Endophilin-A2 12 4 41.5 11
 P54753|EPHB3_HUMAN Ephrin type-B receptor 3 2 2 110.3 5
 Q3B8N2|LEG9B_HUMAN Galectin-9B 10 3 39.7 1, 21, 23
 Q6DKI2|LEG9C_HUMAN Galectin-9C 10 3 39.6 1, 21, 23
 P48307|TFPI2_HUMAN Tissue factor pathway inhibitor 2 10 2 26.9 9, 10
Transmembrane proteins
 P20273|CD22_HUMAN B-cell receptor CD22 11 8 95.3 22
 P21730|C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 8 2 39.3 12, 22
 P08962|CD63_HUMAN CD63 antigen 7 2 25.6 15
 P60033|CD81_HUMAN CD81 antigen 12 2 25.8 2
 P16671|CD36_HUMAN Platelet glycoprotein 4 (CD36) 14 5 53.1 20, 21
 Q15438|CYH1_HUMAN Cytohesin-1 19 2 46.4 14
 Q8WXG9|GPR98_HUMAN G-protein-coupled receptor 98 1 3 693.1 19
 P18462|1A25_HUMAN HLA class I histocompatibility antigen, A-25 alpha chain 8 2 41.2 15
 P30450|1A26_HUMAN HLA class I histocompatibility antigen, A-26 alpha chain 8 2 41.1 15
 P30512|1A29_HUMAN HLA class I histocompatibility antigen, A-29 alpha chain 8 2 40.9 15
 P16189|1A31_HUMA HLA class I histocompatibility antigen, A-31 alpha chain 8 2 41.0 15
 P10314|1A32_HUMAN HLA class I histocompatibility antigen, A-32 alpha chain 17 4 41.0 15, 16
 P16190|1A33_HUMAN HLA class I histocompatibility antigen, A-33 alpha chain 8 2 40.9 15
 P30453|1A34_HUMAN HLA class I histocompatibility antigen, A-34 alpha chain 8 2 41.1 15
 P30456|1A43_HUMAN HLA class I histocompatibility antigen, A-43 alpha chain 8 2 41.0 15
 P30457|1A66_HUMAN HLA class I histocompatibility antigen, A-66 alpha chain 8 2 41.1 15
 P01891|1A68_HUMAN HLA class I histocompatibility antigen, A-68 alpha chain 8 2 40.9 15
 P30459|1A74_HUMAN HLA class I histocompatibility antigen, A-74 alpha chain 17 4 40.9 15, 16
 P04222|1C03_HUMAN HLA class I histocompatibility antigen, Cw-3 alpha 
chain
27 2 40.9 13
 P30505|1C08_HUMAN HLA class I histocompatibility antigen, Cw-8 alpha 
chain
44 2 40.8 13
 P23467|PTPRB_HUMAN Receptor-type tyrosine-protein phosphatase beta 1 2 224.3 12
 Q12913|PTPRJ_HUMAN Receptor-type tyrosine-protein phosphatase eta 3 3 145.9 20
Signaling
 P31947|1433S_HUMAN 14–3–3 protein sigma 5 2 27.8 13
 Q99996|AKAP9_HUMAN A-kinase anchor protein 9 0 2 453.7 13
 Q12802|AKP13_HUMAN A-kinase anchor protein 13 0 3 307.6 3, 4, 7, 10, 13, 15
 P62158|CALM_HUMAN Calmodulin 41 8 16.8 1
 P01112|RASH_HUMAN GTPase HRas 12 2 21.3 10
 P01111|RASN_HUMAN GTPase NRas 12 2 21.2 10
 Q9UMX6|GUC1B_HUMAN Guanylyl cyclase-activating protein 2 32 7 23.4 1, 3, 5, 9
 Q16539|MK14_HUMAN Mitogen-activated protein kinase 14 19 5 41.3 13
 Q9Y314|NOSIP_HUMAN Nitric oxide synthase-interacting protein 30 7 33.2 11
 P49593|PPM1F_HUMAN Protein phosphatase 1F 44 20 49.8 16, 17
 Q13188|STK3_HUMAN Serine/threonine-protein kinase 3 10 4 56.3 18
 O00506|STK25_HUMAN Serine/threonine-protein kinase 25 12 2 48.1 17
 Q9P289|STK26_HUMAN Serine/threonine-protein kinase 26 19 4 46.5 15
 Q86Y07|VRK2_HUMAN Serine/threonine-protein kinase VRK2 7 3 58.1 16
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to Dig-MAA, a strong labeling was observed with the Dig-
SNA lectin at molecular weight corresponding to immuno-
precipitated CD36 from cells overexpressing CD36 or CD36 
and NEU1. These results suggested that CD36 may be modi-
fied predominantly with α-2,6- rather than α-2,3-sialylation. 
We next used a lectin pulldown assay with biotinylated SNA 
to evaluate the effects of kE on the α2-6 sialylation level of 
CD36. As depicted in Fig. 3F, the amount of sialylated CD36 
recovered after SNA pulldown was significantly decreased 
by 47.8 ± 12.7% after incubation of COS-7 cells with kE 
(50 µg/mL). Taken together, these data demonstrated that 
regulation of NEU1 sialidase activity by EDP had functional 
consequences on the sialylation level of CD36.
Similar experiments were performed in human mac-
rophages endogenously expressing both NEU1, CD36 and 
the ERC. As shown in Fig. 4a, colocalization of NEU1 
and CD36 was clearly observed at the plasma mem-
brane of macrophages and prior incubation with kE was 
without effect. Reciprocal co-immunoprecipitations were 
performed from crude membrane preparations of mac-
rophages and efficient cell fractionation was first studied 
by evaluating β2-integrin distribution between the cyto-
sol and crude membrane fractions. Densitometry analysis 
revealed that 91.7 ± 0.9% of β2-integrin was recovered in 
crude membrane fractions (Fig. 4b). Reciprocal co-immu-
noprecipitations showed that endogenous CD36 and NEU1 
interacted together in macrophages (Fig. 4c, d) and that 
prior incubation with kE had no effect, rather suggesting a 
constitutive interaction between CD36 and NEU1. Moreo-
ver, we evaluated if NEU3, another membrane sialidase, 
could interact with CD36. Under the same experimental 
conditions, NEU3 failed to co-immunoprecipitate with 
CD36 (Fig. 4e). These results therefore strengthened the 
specificity of the interaction between NEU1 and CD36.
We next assessed the effect of kE on sialidase activity 
at the plasma membrane of macrophages as previously 
Table 1  (continued)
UnitProt accession number Protein name % coverage Number 
of unique 
peptide
Average 
molecular 
mass (kDa)
Band no.
 Q9UKE5|TNIK_HUMAN TRAF2 and NCK-interacting protein kinase 8 3 154.9 17, 19
 P07948|LYN_HUMAN Tyrosine-protein kinase Lyn 5 2 58.6 16
 Q12866|MERTK_HUMAN Tyrosine-protein kinase Mer 8 7 110.2 23
 Q9UGJ0|AAKG2_HUMAN 5′-AMP-activated protein kinase subunit gamma-2 3 2 63.1 13
 Q96JB6|LOXL4_HUMAN Lysyl oxidase homolog 4 7 4 84.5 19
 P01033|TIMP1_HUMAN Metalloproteinase inhibitor 1 11 2 23.2 5
Cytoskeleton
 O15143|ARC1B_HUMAN Actin-related protein 2/3 complex subunit 1B 20 6 41.0 12
 P59998|ARPC4_HUMAN Actin-related protein 2/3 complex subunit 4 21 4 19.7 1
 Q562R1|ACTBL_HUMAN Beta-actin-like protein 2 39 2 42.0 12, 13
 Q86UX7|URP2_HUMAN Fermitin family homolog 3 6 2 76.0 18, 19, 22
 Q9UGP4|LIMD1_HUMAN LIM domain-containing protein 1 11 5 72.2 19
 P19105|ML12A_HUMAN Myosin regulatory light chain 12A 30 5 19.8 112
 O14950|ML12B_HUMAN Myosin regulatory light chain 12B 30 5 19.8 1
 P24844|MYL9_HUMAN Myosin regulatory light polypeptide 9 17 3 19.8 1
 P07737|PROF1_HUMAN Profilin-1 19 2 15.1 13
 Q13464|ROCK1_HUMAN Rho-associated protein kinase 1 3 4 158.2 23
 Q71U36|TBA1A_HUMAN Tubulin alpha-1A chain 9 3 50.1 1, 2, 10, 11
 Q6PEY2|TBA3E_HUMAN Tubulin alpha-3E chain 28 3 49.9 13
 Q9BVA1|TBB2B_HUMAN Tubulin beta-2B chain 5 2 49.9 11
 P04350|TBB4A_HUMAN Tubulin beta-4A chain 32 4 49.6 11, 12
Vesicle trafficking
 Q92928|RAB1C_HUMAN Putative Ras-related protein Rab-1C 37 5 22.1 1, 4
 Q92546|RGP1_HUMAN RAB6A-GEF complex partner protein 2 12 4 42.5 13, 14
 Q5HYI8|RABL3_HUMAN Rab-like protein 3 22 6 26.4 7
 Q9H0U4|RAB1B_HUMAN Ras-related protein Rab-1B 37 5 22.2 1, 4
 Q14964|RB39A_HUMAN Ras-related protein Rab-39A 26 5 25.0 1
 O43752|STX6_HUMAN Syntaxin-6 9 2 29.2 10
Trypsin-digested protein bands from two independent experiments were analyzed by nano-LC-ESI MS/MS and proteins identified with Mascot 
software in Swiss-Prot and trEMBL databases
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described for dermal fibroblasts [7]. As shown in Fig. 4f, 
incubation with kE significantly increased by 156.4 ± 14.7% 
sialidase activity at the plasma membrane. Compared 
to negative control siRNA, silencing NEU1 by 50  nM 
NEU1 siRNA totally blocked these effects of kE and defi-
nitely demonstrated involvement of NEU1 in kE-induced 
sialidase activity at the plasma membrane of macrophages. 
This NEU1-mediated increase in sialidase activity, in the 
presence of kE, was associated with a significant decrease 
by 41.1 ± 11.4% of the sialylation level of CD36 (Fig. 4g). 
To further confirm that this modulating effect on CD36 
sialylation level involved the ERC, kE was pre-incubated 
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with the V14 peptide (VVGSPSAQDEASPL), a synthetic 
peptide blocking the interaction between the GxxPG motifs 
contained in kE and the ERC [47, 48], prior to its incuba-
tion with cells. In these conditions, the effects of kE were 
blocked (Fig. 4g). Taken together, these results demonstrated 
that both the ERC and its NEU1 subunit were involved in 
these effects.
Elastin‑derived peptides potentiate oxLDL uptake 
in human macrophages
Macrophage CD36 plays a critical role in atherosclerosis 
through its interaction with oxidized low-density lipoprotein 
(oxLDL), which triggers signaling cascades for inflamma-
tory responses, oxLDL uptake and formation of foam cell 
formation, which is the initial critical stage of atheroscle-
rosis. CD36 is thought to be responsible for at least 50% of 
oxLDL uptake by murine and human macrophages [49–51]. 
To determine if EDP would affect the uptake of oxLDL in 
these cells, we evaluated the effects of kE on oxLDL uptake 
using 1,10-dioctadecyl-3,3,3030-tetramethylindocyanide 
percholorate (DiI)-labeled oxLDL (DiI-oxLDL) and fluo-
rescent microscopy as described previously [28]. As shown 
in Fig. 5, pre-incubation of cultured macrophages with kE 
prior to the addition of Dil-oxLDL (10 µg/mL, 4 h) led to a 
significant increase in oxLDL uptake by 40.8 ± 4.7% com-
pared to macrophages without kE (w/o). At higher mag-
nification (Fig. 5, inset), DiI-oxLDL particles were found 
inside in the cells and not bound on the plasma membrane. 
Importantly, the V14 peptide and 2-deoxy-2,3-didehydro-
N-acetylneuraminic acid (DANA), a sialidase inhibitor, 
blocked these potentiating effects of kE and demonstrated 
that both the ERC and NEU1 were involved in these effects. 
If these potentiating effects of EDP arise from their impact 
on the sialylation level of CD36 remains to be investigated.
In conclusion, we have identified herein a new interac-
tion partner of plasma membrane NEU1 in macrophages, 
the scavenger receptor CD36. We showed that EDP, through 
the ERC and its catalytic subunit NEU1, regulate the sialyla-
tion level of CD36 and modulate the uptake of oxLDL in 
these cells. This study strengthens the key role played by this 
plasma membrane sialidase in macrophages and may have 
potential implications in the proatherogenic effects of EDP 
described previously in atherosclerosis [13]. It is tempting 
to speculate that by its ability to form dimeric structures at 
the plasma membrane [16], NEU1 may favor proximity and 
close interaction between the ERC and adjacent receptors for 
potential cross-talk and transactivation of receptors. By their 
ability to modulate the sialylation level of adjacent mem-
brane receptors through NEU1, new roles for EDP and the 
ERC are anticipated in the fine-tuning of membrane receptor 
activation and signaling.
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Fig. 3  Validation of the interaction between NEU1 and CD36 in 
COS-7 cells and functional consequences on the sialylation level of 
CD36. A Colocalization of NEU1 and CD36 at the cell surface of 
COS-7 cells co-expressing human NEU1 and human CD36 by con-
focal microscopy acquisitions. Areas of colocalization at the plasma 
membrane are indicated by white arrows. Images are representative 
of two independent experiments. B FRET experiments in COS-7 
cells expressing CD36-Teal (energy donor) or CD36-Teal and NEU1-
YFP (energy acceptor). Confocal images after spectral unmixing for 
the donor (a, c, e) and the acceptor (b, d, f) in a cell incubated (e, 
f), or not (a–d), with kE (50 µg/mL, 1 h), or without acceptor (a, b). 
Zoom area of calculated FRET efficiency are presented in Fire LUT 
for each condition (g, h). White arrows indicate areas of higher FRET 
efficiency. The graph represents the mean FRET efficiency ± SEM of 
three independent experiments (three cells/experiment). For each cell, 
thirty regions of interest of 0.62 µm2 contouring the cell were chosen. 
Statistical analysis was performed by Student’s t test (***p < 0.001 
versus no acceptor; ns non-significant). Scale bar: 10  µm. C Left 
panel: NEU1-HA was immunoprecipitated with a rabbit monoclonal 
anti-HA antibody from whole lysate of COS-7 cells expressing CD36 
(NEU1-HA−/CD36+) or co-expressing human NEU1-HA and CD36 
(NEU1-HA+/CD36+). Co-immunoprecipitation of CD36 was moni-
tored by Western blot using a mouse monoclonal anti-CD36 antibody 
(1/500). The figure is representative of six independent experiments. 
Right panel: blot quantification by densitometry analysis. Results are 
expressed as mean ± SEM of six independent experiments and nor-
malized to NEU1-HA−/CD36+ condition. Statistical analysis was 
performed by Student’s t test (*p < 0.05). D Left panel: CD36 was 
immunoprecipitated with a mouse monoclonal anti-CD36 antibody 
from whole lysate of COS-7 cells expressing NEU1-HA (CD36−/
NEU1-HA+) or co-expressing NEU1-HA and CD36 (CD36+/NEU1-
HA+). Co-immunoprecipitation of NEU1-HA was monitored by 
Western blot using a rabbit monoclonal anti-HA antibody (1/1000). 
The figure is representative of four independent experiments. Right 
panel: blot quantification by densitometry analysis. Results are 
expressed as mean ± SEM of four independent experiments and nor-
malized to CD36−/NEU1-HA+ condition. Statistical analysis was 
performed by Student’s t test (**p < 0.01). E Lectin blotting after 
immunoprecipitation of CD36 from whole lysates of COS-7 cells 
expressing CD36 (CD36) or co-expressing CD36 and NEU1 (CD36/
NEU1). Nitrocellulose membranes were incubated with digoxigenin-
labeled SNA or MAA lectins followed by anti-digoxigenin antibod-
ies coupled to alkaline-phosphatase according to the manufacturer’s 
instructions. Detection of immunoprecipitated CD36 was revealed 
as described above. The figure is representative of two independent 
experiments. F Left panel: SNA pulldown of crude membrane prep-
arations of COS-7 cells expressing NEU1 (NEU1) or co-expressing 
CD36 and NEU1 (CD36/NEU1), and incubated, or not, with kE 
(50  µg/mL, 1  h). For each condition, equal amount of proteins was 
used. The amount of sialylated CD36 recovered after SNA pulldown 
was evaluated by Western blot using a mouse monoclonal anti-CD36 
antibody as described above. The figure is representative of three 
independent experiments. Right panel: quantification of the sialyla-
tion level of CD36 (pulldown/lysate ratio) by densitometry analysis. 
The sialylation level of CD36 was normalized to the control condi-
tion (without kE, w/o). Results are expressed as mean ± SEM of three 
independent experiments and statistical analysis was performed by 
Student’s t test (*p < 0.05)
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Fig. 4  Validation of the interaction between NEU1 and CD36 in 
human macrophages and functional consequences on the sialylation 
level of CD36. a Colocalization of NEU1 and CD36 at the cell sur-
face of macrophages differentiated from THP-1 cells, and stimulated, 
or not, with kE (50 µg/mL, 1 h), by confocal microscopy acquisitions. 
Areas of colocalization at the plasma membrane are indicated by 
white arrows. Images are representative of two independent experi-
ments. b Left panel: distribution of the β2-integrin between the cyto-
sol and crude membrane fractions (30  µg each) of macrophages by 
Western blot using a mouse monoclonal anti β2-integrin (1/500). 
The figure is representative of three independent experiments. Right 
panel: blots quantification by densitometry analysis. Results are 
expressed as mean ± SEM of three independent experiments and sta-
tistical analysis was performed by Student’s t test (***p < 0.001). c 
NEU1 was immunoprecipitated with a rabbit polyclonal anti-NEU1 
antibody from crude membrane preparations of macrophages and 
co-immunoprecipitation of CD36 was monitored by Western blot 
using a mouse monoclonal anti-CD36 antibody. The figure is repre-
sentative of three independent experiments. d CD36 was immunopre-
cipitated with a mouse monoclonal anti-CD36 antibody from crude 
membrane preparations of macrophages and co-immunoprecipitation 
of NEU1 was monitored by Western blot using a rabbit polyclonal 
anti-NEU1 antibody (1/500). The figure is representative of two 
independent experiments. e CD36 was immunoprecipitated with a 
mouse monoclonal anti-CD36 antibody from whole lysate of mac-
rophages and co-immunoprecipitation of NEU3 was monitored by 
Western blot using a rabbit polyclonal anti-NEU3 antibody (1/500). 
The figure is representative of three independent experiments. f Up 
panel: sialidase activity at the plasma membrane of adherent mac-
rophages was measured using 400  µM of 2′-(4-methylumbelliferyl)-
α-d-N-acetylneuraminic acid substrate in 20  mM  CH3COONa (pH 
6.5) before and after incubation with kE (50  µg/mL, 2  h). Mac-
rophages were either non-transfected or transfected with 50 nM nega-
tive control siRNA (siCont) or NEU1 siRNA (siNEU1). Results are 
expressed as mean ± SEM of three to nine independent experiments 
and normalized to the control (non-transfected, without kE). Statis-
tical analysis was performed by one-way ANOVA followed by a 
Dunnett’s multiple comparisons test (***p < 0.001; ns non-signifi-
cant). Down panel: expression level of NEU1 in macrophages trans-
fected with 50 nM negative control siRNA (siCont) or NEU1 siRNA 
(siNEU1) and monitored by Western blot using a rabbit polyclonal 
anti-NEU1 antibody. The blot is representative of three independent 
experiments (left). Blots were quantified by densitometry analysis, 
and results expressed as mean ± SEM of three independent experi-
ments and normalized to negative control siRNA (siCont). Statistical 
analysis was performed by Student’s t test (**p < 0.01. g SNA pull-
down of crude membrane preparations of macrophages incubated, or 
not, with kE (50 µg/mL), V14 + kE (molar ratio 2:1) or V14 peptide 
alone for 1 h at 37 °C. For each condition, equal amount of proteins 
was used. The amount of sialylated CD36 recovered after SNA pull-
down was evaluated and quantified as depicted in Fig. 3F. The sialyla-
tion level of CD36 was normalized to the respective control (w/o or 
V14) and results expressed as mean ± SEM of three to five independ-
ent experiments. Statistical analysis was performed by Student’s t test 
(*p < 0.05; ns non-significant)
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